8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (May 21, 2019)

Filed May 21, 2019For Securities:ALNY

Summary

This 8-K filing reports the closing of the Equity Transaction between Alnylam Pharmaceuticals, Inc. (ALNY) and Regeneron Pharmaceuticals, Inc. As of May 21, 2019, Regeneron has purchased approximately $400 million worth of newly issued Alnylam common stock, acquiring a 4% ownership stake. This transaction, priced at $90.00 per share, was previously announced on April 8, 2019, and marks a significant strategic investment by Regeneron. The closing of this equity transaction also signifies the effectiveness of the Master Agreement governing their collaboration and the Investor Agreement between the two companies. Investors should note that this filing confirms the completion of the previously disclosed equity placement, reinforcing the financial and strategic partnership between Alnylam and Regeneron.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. purchased 4,444,445 shares of Alnylam's common stock.
  • 2The aggregate cash consideration for the share purchase was $400 million.
  • 3Regeneron acquired an approximate 4% ownership position in Alnylam.
  • 4The purchase price per share was $90.00.
  • 5The Equity Transaction closed on May 21, 2019, following the expiration of the Hart-Scott-Rodino waiting period.
  • 6The Master Agreement governing the collaboration between Alnylam and Regeneron became effective upon closing.
  • 7The Investor Agreement between Alnylam and Regeneron also became effective upon closing.

Frequently Asked Questions

Regeneron's purchase of $400 million in Alnylam's common stock at $90.00 per share represents a significant strategic investment and a strengthened partnership between the two companies. It also provides Alnylam with substantial capital and validates Regeneron's confidence in Alnylam's prospects.

The Master Agreement governs the ongoing collaboration between Alnylam and Regeneron. While not detailed in this 8-K, its effectiveness signifies the formal commencement or continuation of joint research, development, or commercial activities between the companies as per their agreed terms.

The Investor Agreement likely outlines the rights and responsibilities of Regeneron as a significant shareholder in Alnylam, potentially including aspects like board representation, information rights, or certain governance provisions, in addition to the terms of the equity transaction and collaboration.

This filing specifically addresses the equity transaction and the Master Agreement with Regeneron. It does not indicate any adverse impact on Alnylam's other existing collaborations, but rather strengthens its financial position and a key strategic partnership.